DelveInsight has launched a new report on Sialorrhea Pipeline Insight, 2020
Sialorrhea Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sialorrhea market. A detailed picture of the Sialorrhea pipeline landscape is provided, which includes the disease overview and Sialorrhea treatment guidelines. The assessment part of the report embraces in-depth Sialorrhea commercial assessment and clinical assessment of the Sialorrhea pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhea collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Sialorrhea, also known as ptyalis,is the condition of excessive drooling in children with cerebral palsy and adults who suffers from neurodegenerative disorders. Drooling is of two types, anterior and posterior drooling. Anterior drooling is defined as saliva spilled from the mouth that is clearly visible. When saliva spills through the oropharynx and into the hypopharynx it is known as posterior drooling.
Click here for :- Free sample page
Pipeline Development Activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Sialorrhea with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Sialorrhea treatment.
- Sialorrhea key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Sialorrhea market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Report key facts:-
- According to DelveInsight’s estimatesin 2017, there were 2,484,780 cases of Sialorrhea in 7MM amongst which United States accounted for most prevalent cases, with 1,132,426 cases in 2017.
- Among EU5 Countries Spain accounted for least number of prevalent population of Sialorrheawith 180,184cases in 2017.
- For the 5 major European Markets (EU5), the total number of prevalent cases of Sialorrhea were 999,549 in 2017, with highest prevalent cases observed in the Germany.
Some of key companies are working on this disease which are given below:-
- US WorldMeds
- Merz Pharma
- NeuoHealing Pharmaceuticals
- Orient Pharma
Name of drugs covered which are given below-
1. Report Introduction
3. Sialorrhea Current Treatment Patterns
4. Sialorrhea – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Sialorrhea Late Stage Products (Phase-III)
7. Sialorrhea Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Sialorrhea Discontinued Products
13. Sialorrhea Product Profiles
14. Sialorrhea Key Companies
15. Sialorrhea Key Products
16. Dormant and Discontinued Products
17. Sialorrhea Unmet Needs
18. Sialorrhea Future Perspectives
19. Sialorrhea Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States